Chronic vs Acute Rejection: Understanding the Difference

Rejection remains the principal immunologic barrier to long-term transplant success. While modern immunosuppressive therapy has dramatically reduced acute rejection rates in the first year, chronic rejection continues to exact a heavy toll on long-term graft survival. Understanding the differences between these two processes — their mechanisms, clinical presentations, diagnostic criteria, and therapeutic responses — is fundamental knowledge for transplant recipients and their caregivers.

Acute Rejection: Time Course and Mechanism

Acute rejection is defined by its relatively rapid onset — days to months after transplantation, or after any reduction in immunosuppression — and by a brisk immunologic response that is potentially reversible with treatment. The dominant mechanism in most acute cellular rejection episodes is T-lymphocyte-mediated attack on donor cells, driven by recognition of allogeneic HLA antigens. CD4+ helper T cells orchestrate the response, activating CD8+ cytotoxic T cells that directly kill donor cells and releasing inflammatory cytokines that recruit macrophages and NK cells to the graft.

Antibody-mediated acute rejection (acute AMR) involves donor-specific antibodies targeting graft endothelium, activating complement (evidenced by C4d deposition in capillaries), and triggering a microvascular inflammatory response. DSA-mediated injury is particularly aggressive in the setting of "de novo" antibodies — those formed after transplantation rather than pre-existing — and is less responsive to standard anti-rejection therapy than cellular rejection.

Chronic Rejection: Mechanism and Timeline

Chronic rejection develops gradually over months to years, representing ongoing, often subclinical immune-mediated injury to the graft vasculature and parenchyma. The hallmark pathological finding is chronic allograft vasculopathy — concentric proliferation of smooth muscle cells and fibroblasts in the intima of graft arteries, leading to progressive luminal narrowing and ischemia. This process is driven by a combination of alloimmune injury, ischemia-reperfusion injury, and non-immunological factors including hypertension, dyslipidemia, diabetes, and viral infections (particularly CMV).

In the kidney, chronic rejection manifests as interstitial fibrosis and tubular atrophy (IFTA), progressive decline in GFR, and proteinuria. In the heart, it presents as cardiac allograft vasculopathy (CAV) — diffuse intimal hyperplasia that may not cause the typical chest pain of atherosclerotic coronary disease because the cardiac transplant is denervated. In the lung, chronic allograft dysfunction (CLAD), primarily bronchiolitis obliterans syndrome, involves progressive obliteration of small airways.

Clinical Presentation: How They Differ

Acute rejection typically presents with a relatively abrupt change in graft function — rising creatinine, spiking liver enzymes, declining spirometry — often accompanied by constitutional symptoms (fever, malaise, graft tenderness). The tempo is days to weeks. Chronic rejection progresses insidiously over months to years, often detectable initially only by laboratory trends (slowly rising creatinine, gradually declining lung function) rather than acute symptoms. By the time symptoms of graft failure become apparent in chronic rejection, substantial irreversible damage has typically already occurred.

Diagnosis

Both forms require tissue biopsy for definitive diagnosis, but the histological features differ. Acute cellular rejection shows active inflammatory infiltrates — lymphocytes within tubular epithelium (tubulitis), endothelialitis, and interstitial inflammation. Chronic rejection shows fibrosis, vascular intimal thickening, tubular atrophy, and loss of normal tissue architecture without the acute inflammatory infiltrate. Modern Banff classification criteria accommodate both types and their overlap, guiding treatment decisions.

Non-invasive monitoring is more advanced for detecting subclinical processes. Donor-derived cell-free DNA (dd-cfDNA) — fragments of donor DNA released from dying graft cells — is elevated during both acute and chronic injury and provides a sensitive early warning signal. Gene expression profiling of peripheral blood can distinguish stable allografts from those undergoing rejection. These tools are increasingly integrated into clinical monitoring protocols.

Treatment and Prognosis

Acute rejection, particularly acute cellular rejection, responds well to high-dose corticosteroid therapy (methylprednisolone pulses). Steroid-resistant acute cellular rejection is treated with thymoglobulin (rabbit anti-thymocyte globulin). Acute AMR is more difficult to treat and typically requires plasmapheresis to remove circulating DSA, IV immunoglobulin (IVIG) for immunomodulation, rituximab (anti-CD20) to deplete antibody-producing B cells, and bortezomib (a proteasome inhibitor) to target plasma cells. With prompt treatment, the majority of acute rejection episodes are reversible with minimal long-term graft damage.

Chronic rejection currently has no established therapy capable of reversing established fibrosis and vasculopathy. Management focuses on optimizing immunosuppression to prevent further injury, aggressively controlling risk factors (hypertension, dyslipidemia, diabetes), treating or preventing contributing infections (CMV prophylaxis), and managing the complications of progressive graft dysfunction. Retransplantation remains the only definitive treatment for end-stage chronic rejection. For a guide to the medications used to prevent and treat rejection, see our overview of immunosuppression therapy after transplant.

For more information and resources, visit our homepage or explore our resources section.